Compositions and methods for treatment of edema
US-12144805-B2 · Nov 19, 2024 · US
Therapeutic agent for vascular disorder
US12564576B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12564576-B2 |
| Application number | US-202117998195-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 7, 2021 |
| Priority date | May 8, 2020 |
| Publication date | Mar 3, 2026 |
| Grant date | Mar 3, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An object is to provide a drug that effectively treats a vascular disorder caused by excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell. Provided are [1] a therapeutic agent for a vascular disorder associated with excessive synthesis and secretion of a type IV collagen protein; [2] a therapeutic agent for a disease caused by excessive synthesis and secretion of a type IV collagen protein; [3] a pharmaceutical composition for treatment of a vascular disorder associated with excessive synthesis and secretion of a type IV collagen protein; [4] a pharmaceutical composition for treatment of a disease caused by excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell; and [5] an agent that inhibits excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell, each of [1] to [5] containing sirolimus as an active ingredient.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A method for treating a peripheral vascular disorder in a subject in need thereof, the peripheral vascular disorder being associated with excessive synthesis and secretion of a type IV collagen protein expressed by type IV collagen α5 or α6 genes, the method comprising administering a pharmaceutical composition comprising sirolimus as an active ingredient. 2 . The method according to claim 1 , wherein the peripheral vascular di…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K31/436Primary
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12564576B2 cover?
- An object is to provide a drug that effectively treats a vascular disorder caused by excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell. Provided are [1] a therapeutic agent for a vascular disorder associated with excessive synthesis and secretion of a type IV collagen protein; [2] a therapeutic agent for a disease caused by excessive synthesis and …
- Who is the assignee on this patent?
- Univ Kumamoto Nat Univ Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/436. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 03 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).